Abstract
Velders MA, Wallentin L, Becker RC, et al. Am Heart J. Epub ahead of print March 2015. DOI: dx.doi.org/10.1016/j.ahj.2015.02.019.
Further cardiovascular events after ST-elevation myocardial infarction (STEMI) are common, even though outcomes have been substantially improved by early primary percutaneous coronary intervention (PPCI). This sub-study of the PLATO (PLATelet inhibition and patient Outcomes) trial included 5395 patients and evaluated three biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP], GDF-15 [growth differentiation factor-15] and high-sensitivity cardiac troponin T) for the prediction of subsequent events in patients with STEMI treated with PPCI.
Only NT-proBNP and GDF-15 showed prognostic value for spontaneous MI during one-year follow-up (both P < 0.0001), with a net reclassification index of 0.22 and 0.05, respectively, when added to baseline clinical characteristics and angiographic extent of coronary artery disease.
It was concluded that for incremental risk stratification in patients with STEMI treated with PPCI, NT-proBNP and GDF-15 would provide additional information to what is currently available to clinicians.